Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients.
BANS produced significant reductions in nasal congestion and discharge scores, and improved patients' sense of smell (morning only), versus placebo, and Peak nasal inspiratory flow (PNIF) increased significantly during BANS treatment.
Efficacy of an Aqueous and a Powder Formulation of Nasal Budesonide Compared in Patients with Nasal Polyps
Sinus symptom scores was significantly more reduced in the Aqua compared to the Turbuhaler treated group, and both reduced symptom scores were significantly better compared to placebo, but there was no statistical difference between the two actively treated groups.
Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps.
- R. Jankowski, C. Schrewelius, V. Strunski
- MedicineArchives of otolaryngology--head & neck surgery
- 1 April 2001
Doses of budesonide aqueous nasal spray, 128 microg once daily, were found to be effective in the treatment of nasal polyps, and doses of budsonide aQueous nasal Spray, 256 microg twice daily, did not show any significant additional efficacy.
A Comparison of Aqueous Suspensions of Budesonide Nasal Spray (128 μg and 256 μg Once Daily) and Fluticasone Propionate Nasal Spray (200 μg Once Daily) in the Treatment of Adult Patients with…
- M. Stern, R. Dahl, L. Nielsen, B. Pedersen, C. Schrewelius
- MedicineAmerican journal of rhinology
- 1 July 1997
Analysis of symptom scores on days when the pollen count was greater than 10 grains/m3 revealed 256 μg/day of budesonide therapy to be significantly more effective in reducing combined symptom scores as well as the individual scores for sneezing and runny nose, compared with 200 μg/ day fluticasone propionate.
Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis
- C. Ahlström-Emanuelsson, M. Andersson, C. Persson, C. Schrewelius, L. Greiff
- MedicineClinical and experimental allergy : journal of…
- 1 May 2004
The rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug roflePonide.
Ostial function in allergic rhinitis.
It seems that pollen does not reach the ostial region, and there were no statistical significant differences in ostial diameter change between the treatment groups except between budesonide and placebo.
A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis.
It is concluded that budesonide, 280 micrograms once daily, reduces polyp size and relieves symptoms in patients with nasal polyposis.
Randomised trial of efficacy and tolerability of budesonide aqueous nasal spray in patients with chronic rhinosinusitis
This study evaluated the efficacy and tolerability of budesonide in an aqueous nasal spray (BANS) in patients with chronic rhinosinusitis. In this double-blind, placebo-controlled, multicentre,…
Budesonide aqueous nasal spray (BANS: Rhinocort® aqua™) is effective as monotherapy in stable patients with chronic rhinosinusitis (CRS)
Clinical efficacy of budesonide in the treatment of eczematous external otitis
- S. Jacobsson, G. Karlsson, P. Rignér, E. Sanner, C. Schrewelius
- MedicineEuropean Archives of Oto-Rhino-Laryngology
Budesonide treatment was associated with a reduction in severity of all symptoms recorded and a marked improvement in erythema, swelling and discharge.